Controlling alpha in a clinical trial: the case for secondary endpoints
Stat Med
.
2000 Mar 30;19(6):763-6.
doi: 10.1002/(sici)1097-0258(20000330)19:6<763::aid-sim517>3.0.co;2-8.
Author
R B D'Agostino Sr
PMID:
10734279
DOI:
10.1002/(sici)1097-0258(20000330)19:6<763::aid-sim517>3.0.co;2-8
No abstract available
Publication types
Comment
Editorial
MeSH terms
Clinical Trials as Topic*
Data Interpretation, Statistical*
Humans
Research Design